Alendronate in patients with calcium nephrolithiasis and loss of bone mass

Central European Journal of Medicine, 05/16/2012

The use of weekly alendronate in patients with recurrent calcium lithiasis and loss of bone mass is safe and effective, curbs lithiasic disease progression, and improves bone mineral density.

Methods

  • The authors present a unique cohort (before and after study) of 15 patients with recurrent calcium nephrolithiasis and loss of bone mass treated for three years with 70 mg sodium alendronate weekly.
  • The sample is divided into two groups by sex (5 men and 10 women, aged 35–65 years).
  • The authors assessed clinical progress of both bone and lithiasic disease and urine and plasma markers of both pathologies.

Results

  • The authors obtained a significant decrease in calcuria levels after 3 years of treatment (15.1 vs. 10.1; p=0.01), fasting calcium/creatinine quotient (0.16 vs. 0.10; p=0.002), and β–crosslaps (0.596 vs. 0.501; p=0.01).
  • Moreover, the authors observed a disease stabilization in 14 of the 15 patients (93.3%), and, in all patients, bone mineral density had improved.
  • Neither side effects nor losses of patients were observed after 3 years of treatment.

Print Article Summary Cat 2 CME Report